Antithrombin III in patients with severe sepsis - A multinational, double-blind, randomized, placebo-controlled phase-III study.

被引：0
|
作者：
Opal, S
Heinrichs, H
Mescheder, A
Keinecke, HO
Knaub, S
机构：
[1] Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA
[2] Centeon Pharma GMBH, Marburg, Germany
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3444
引用
收藏
页码：108B / 108B
页数：1
相关论文
共 50 条
  • [31] PHASE-III RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RHGM-CSF FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
    NEMUNAITIS, J
    ROSENFELD, CS
    ASH, R
    FREEDMAN, MH
    DEEG, HJ
    APPELBAUM, F
    SINGER, JW
    FLOMENBERG, N
    DALTON, W
    ELFENBEIN, GJ
    RIFKIN, R
    RUBIN, A
    AGOSTI, J
    HAYES, FA
    HOLCENBERG, J
    SHADDUCK, RK
    BONE MARROW TRANSPLANTATION, 1995, 15 (06) : 949 - 954
  • [32] THE PRODERM STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG (OCTAGAM 10%) IN PATIENTS WITH ACTIVE DERMATOMYOSITIS
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M. M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beck-Mann, I.
    Clodi, E.
    Levine, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 428 - 429
  • [33] A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF NEUCARDIN™ IN PATIENTS WITH CHRONIC HEART FAILURE
    Gao, Runlin
    Zhang, Jian
    Liu, Heping
    Wang, Lina
    Pang, Xiaohua
    Fu, Lu
    Meng, Fanbo
    Zhou, Mingdong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 668 - 668
  • [34] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
    Gommoll, Carl
    Durgam, Suresh
    Mathews, Maju
    Forero, Giovanna
    Nunez, Rene
    Tang, Xiongwen
    Thase, Michael E.
    DEPRESSION AND ANXIETY, 2015, 32 (06) : 451 - 459
  • [35] Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy
    Elizabeth Hovey
    Paul de Souza
    Gavin Marx
    Phillip Parente
    Tal Rapke
    Andrew Hill
    Antonino Bonaventura
    Antony Michele
    Paul Craft
    Ehtesham Abdi
    Andrew Lloyd
    Supportive Care in Cancer, 2014, 22 : 1233 - 1242
  • [36] Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients
    Baba, Masayuki
    Matsui, Norimitsu
    Kuroha, Masanori
    Wasaki, Yosuke
    Ohwada, Shoichi
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (05) : 1299 - 1306
  • [37] Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy
    Hovey, Elizabeth
    de Souza, Paul
    Marx, Gavin
    Parente, Phillip
    Rapke, Tal
    Hill, Andrew
    Bonaventura, Antonino
    Michele, Antony
    Craft, Paul
    Abdi, Ehtesham
    Lloyd, Andrew
    SUPPORTIVE CARE IN CANCER, 2014, 22 (05) : 1233 - 1242
  • [38] Opicapone EPSILON study in early Parkinson's: design of a phase III, double-blind, randomized, placebo-controlled study
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Stocchi, F.
    Antonini, A.
    Moreira, J.
    Rocha, J.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 719 - 719
  • [39] Talactoferrin Alfa Reduces Mortality In Severe Sepsis: Results Of A Phase 2 Randomized, Placebo-controlled, Double-blind Study
    Guntupalli, K. K.
    Dean, N. C.
    Morris, P. E.
    Bandi, V.
    Margolis, B. D.
    Rivers, E.
    Levy, M. M.
    Lodato, R. F.
    Schaumberg, J.
    Malik, R. K.
    Dellinger, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [40] A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
    Mizuno, Yoshikuni
    Hattori, Nobutaka
    Kondo, Tomoyoshi
    Nomoto, Masahiro
    Origasa, Hideki
    Takahashi, Ryosuke
    Yamamoto, Mitsutoshi
    Yanagisawa, Nobuo
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (05) : 201 - 207
12345